Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages-Reference-Cited by-同舟云学术

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages

Published:2023-04 Issue:4 Volume:26 Page:106413
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Touret Franck^ORCID,Giraud Emilie,Bourret Jérôme,Donati Flora,Tran-Rajau Jaouen,Chiaravalli Jeanne,Lemoine Frédéric,Agou Fabrice,Simon-Lorière Etienne,van der Werf Sylvie,de Lamballerie Xavier

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference32 articles.

1. Neutralizing monoclonal antibodies for treatment of COVID-19;Taylor;Nat. Rev. Immunol.,2021

2. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail;Dong;Nat. Microbiol.,2021

3. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody;Pinto;Nature,2020

4. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution;Cao;Nature,2023

5. Emergence of SARS-CoV-2 omicron lineages BA.4 and BA.5 in South Africa;Tegally;Nat. Med.,2022

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement;Immunological Reviews;2024-09-13

2. Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways;Nature Communications;2024-08-12

3. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2;Clinical Microbiology and Infection;2024-08

4. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages;Biomedicine & Pharmacotherapy;2024-08

5. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients;Journal of Antimicrobial Chemotherapy;2024-07-29